Coherus Biosciences Signals Confident Oncology Earnings Outlook

Coherus Biosciences ((CHRS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Coherus Biosciences’ latest earnings call struck a cautiously optimistic tone, as management highlighted strong LOQTORZI growth, record patient starts and solid trial progress, all supported by a fresh $54 million capital raise. These gains were balanced by seasonality, storm-related revenue losses and lingering uncertainty around CCR8 programs and data maturity.

LOQTORZI Delivers 61% Year-Over-Year Sales Growth

LOQTORZI net sales climbed 61% versus Q1 2025 to $11.8 million, underscoring robust year-over-year momentum despite a softer quarter sequentially. Revenue dipped about 4.8% from Q4 2025’s $12.4 million, which management framed as a manageable pause within a longer-term ramp profile.

Record New Patient Starts Support Demand Outlook

The quarter produced all-time high new patient starts for LOQTORZI, with both the breadth and depth of ordering accounts up 21%. Management said treatment duration is rising quarter-over-quarter, reinforcing its view that average demand can grow 10% to 15% per quarter through 2026.

CATALYST-202 Trial Reaches Full Enrollment

Coherus completed target accrual for the randomized 72-patient CATALYST-202 study in first-line hepatocellular carcinoma, with initial data expected midyear. Prior triplet data for casdozokitug showed an objective response rate of 38% and a 17% complete response rate, outperforming historical benchmarks and supporting deeper biomarker work.

Tagmokitug Program Accelerates Across Multiple Tumor Types

Multiple tagmokitug cohorts are now actively accruing, including 40-patient expansions in head and neck squamous cell carcinoma and upper GI adenocarcinoma, plus ESCC and MSS CRC without liver metastases. Initial data from several of these cohorts are anticipated between midyear and the second half of 2026, with a first nonproprietary combo in prostate cancer starting in the fall.

Favorably Positioned CCR8 Candidate Amid Mixed Class Data

Management argued tagmokitug has the “right drug” profile, citing linear dose-dependent pharmacokinetics, strong target binding, dose-dependent immune effects and a tolerable safety profile alone and with toripalimab. This positioning is important as investors digest mixed CCR8-class results from competitors, which heighten binary risk but also may differentiate stronger assets.

Cost Discipline and Capital Raise Bolster Liquidity

Coherus strengthened its balance sheet with $54 million of net proceeds from a follow-on equity offering, ending the quarter with $167 million in cash, equivalents and investments. Operating expenses moved lower, with R&D from continuing operations down about 11.9% year-over-year to $21.5 million and SG&A down 11.2% to $23.1 million.

Seasonality and Storms Pressure Q1 Revenue

Management attributed the quarter’s modest LOQTORZI revenue decline to typical oncology seasonality, compounded by severe winter storms. An internal analysis of an 85-product oncology basket showed a roughly 10% Q4-to-Q1 drop in 2026 versus a historical 5%, as patients on 2- and 3-week infusion schedules missed entire cycles.

CCR8 Field Volatility Raises Execution Risk

The competitive landscape for CCR8 therapies remains unsettled, with one major player halting enrollment after limited responses and others reporting more encouraging activity. Coherus stressed that ultimate outcomes will hinge on pharmacology and target strategy, but acknowledged that class-level volatility increases perception and execution risk around upcoming tagmokitug readouts.

Early Readouts May Leave Key Questions Open

Several midyear data drops will cover only a portion of enrolled patients, with the company expecting around half of some cohorts to be reportable. Management cautioned that pivotal regulatory endpoints like durability of response and overall survival will require longer follow-up, potentially delaying definitive go/no-go and approval decisions.

Cash Usage Ticks Down but Runway in Focus

The quarter closed with $167 million in cash, down modestly from $172.1 million at year-end, even after the equity raise, as clinical investments continued. Coherus believes current resources are sufficient through key 2026–2027 data events, yet it highlighted that achieving roughly $175 million in annual LOQTORZI revenue will be important to cover core cash burn over time.

Lean R&D Footprint Brings Both Savings and Constraints

R&D spending fell nearly 12% year-over-year, driven partly by reduced headcount and infrastructure following the biosimilars exit. While this supports a leaner operating model, it may limit flexibility if multiple positive readouts emerge and rapid expansion or additional trials are needed simultaneously.

Weather-Related Treatment Loss Seen as Permanent

Executives emphasized that missed treatment cycles due to winter storms are effectively lost revenue, as a skipped 3-week cycle does not get “made up” later. That dynamic creates a permanent under-delivery of Q1 doses that is unlikely to be fully recovered in subsequent quarters, even if demand trends remain strong.

Guidance: LOQTORZI Ramp Targets and Funding Horizon

The company reiterated LOQTORZI guidance, aiming to reach about $15 million in quarterly sales sometime in 2026, $30 million to $35 million per quarter in 2027 and roughly $44 million per quarter, or $175 million annually, by 2028. Coherus expects 10% to 15% average quarterly demand growth in 2026, sees itself funded through key 2026–2027 readouts and plans to issue full-year 2026 revenue guidance in August.

Coherus’ call painted a picture of a company transitioning into a focused oncology player, with LOQTORZI gaining traction and an expanding immuno-oncology pipeline backed by a cleaner balance sheet. Investors will now watch whether midyear data, CCR8 differentiation and steady execution can validate the growth story and offset near-term volatility from seasonality and external class risk.